Stock Price Movement and Market Context
On 25 Nov 2025, Shree Ganesh Biotech India’s share price touched Rs.0.62, representing its lowest level in the past year and also an all-time low. This price point is notably below the stock’s 52-week high of Rs.1.19, reflecting a decline of nearly 48%. The stock underperformed its sector, with a day change of -1.54%, lagging behind the Pharmaceuticals & Biotechnology sector’s broader trends. While the Agriculture sector gained 3.8% on the same day, Shree Ganesh Biotech India’s shares traded below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent downward momentum.
Comparative Market Performance
The broader market environment showed resilience, with the Sensex opening higher at 85,008.93 points and trading close to its 52-week high of 85,801.70, just 0.99% away. The Sensex was supported by bullish moving averages, with the 50-day moving average positioned above the 200-day moving average. Mid-cap stocks led the market gains, with the BSE Mid Cap index rising by 0.16%. In contrast, Shree Ganesh Biotech India’s one-year stock performance reflected a decline of 38.46%, while the Sensex recorded a positive return of 6.05% over the same period.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Financial Performance and Profitability Metrics
Shree Ganesh Biotech India’s financial data for the nine months ending September 2025 reveals a contraction in net sales to Rs.5.16 crores, reflecting a decline of 44.64% compared to the previous period. Correspondingly, the company reported a net loss after tax (PAT) of Rs.-0.61 crores, also showing a reduction of 44.64%. These figures indicate a challenging revenue environment and continued pressure on profitability.
The company’s return on equity (ROE) averaged 2.62%, which suggests limited profitability relative to shareholders’ funds. Additionally, the EBIT to interest coverage ratio averaged 0.91, highlighting constraints in servicing debt obligations effectively. The debtors turnover ratio for the half-year period stood at 0.00 times, signalling potential issues in receivables management or collection efficiency.
Valuation and Risk Considerations
From a valuation perspective, Shree Ganesh Biotech India’s stock is trading at levels considered risky relative to its historical averages. Over the past year, the company’s profits have declined by approximately 86.6%, while the stock price has fallen by 38.46%. This divergence underscores the challenges faced by the company in translating operational results into market value.
The majority of the company’s shares are held by non-institutional investors, which may influence liquidity and trading dynamics. The stock’s current position below all major moving averages further emphasises the subdued market sentiment surrounding the company.
Shree Ganesh Biotech India or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Sector and Industry Overview
Operating within the Pharmaceuticals & Biotechnology sector, Shree Ganesh Biotech India faces a competitive landscape where innovation, regulatory compliance, and financial stability are critical. The sector has shown mixed performance, with some segments advancing while others face headwinds. The company’s current market cap grade is moderate, but its financial indicators suggest challenges in sustaining growth and profitability.
Summary of Key Financial Indicators
To summarise, the company’s key financial metrics for the recent period include:
- Net sales of Rs.5.16 crores for nine months, down 44.64%
- Net loss after tax of Rs.-0.61 crores for nine months, down 44.64%
- Return on equity averaging 2.62%
- EBIT to interest coverage ratio averaging 0.91
- Debtors turnover ratio at 0.00 times for half-year
These figures collectively illustrate the financial pressures faced by Shree Ganesh Biotech India, which have contributed to the stock’s decline to its 52-week low.
Market Sentiment and Trading Patterns
The stock’s trading below all major moving averages indicates a persistent downtrend, with short-term and long-term technical indicators aligning to reflect subdued investor confidence. The day’s performance, with a decline of 1.54%, further emphasises the stock’s underperformance relative to its sector and the broader market indices.
In contrast, the Sensex and mid-cap indices have demonstrated resilience, suggesting that the challenges faced by Shree Ganesh Biotech India are company-specific rather than reflective of broader market trends.
Conclusion
Shree Ganesh Biotech India’s fall to a 52-week low of Rs.0.62 is underpinned by a combination of declining sales, net losses, and financial ratios that point to limited profitability and debt servicing capacity. The stock’s position below all key moving averages and its underperformance relative to sector and market benchmarks highlight the current challenges faced by the company within the Pharmaceuticals & Biotechnology sector.
While the broader market and sector indices have shown positive momentum, Shree Ganesh Biotech India’s financial and trading data indicate a cautious outlook based on recent performance metrics.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
